Pitavastatin and Ezetimibe Combination

"Expanding the Cardiovascular Treatment Portfolio"

Bukwang Pharmaceutical announced on August 5 that it will launch "Erozet Tablets 1/10 mg (containing pitavastatin and ezetimibe)," a low-dose combination drug for dyslipidemia.


This product is used as an adjunct to diet to decrease elevated total cholesterol (total-C), LDL-cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and non-HDL cholesterol in patients with primary hypercholesterolemia (both heterozygous familial and non-familial) or mixed dyslipidemia, while increasing HDL-cholesterol (HDL-C).


Erojettab, a low-dose combination tablet for dyslipidemia. Bukwang Pharmaceuticals

Erojettab, a low-dose combination tablet for dyslipidemia. Bukwang Pharmaceuticals

View original image

Bukwang Pharmaceutical has newly added a low-dose option to its existing pitavastatin and ezetimibe combination lineup. The company aims to fill the therapeutic gap between low- and high-dose statin monotherapy and to create a prescription environment that considers patient tolerability.



A representative from Bukwang Pharmaceutical said, "We are now able to offer healthcare professionals and patients a more diverse and flexible range of prescription options in the dyslipidemia treatment field."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing